According to a research collaboration among UCLA investigators and Merck KGaA, berzosertib has shown promise for Covid-19 and is also being touted for the drug’s unusually broad effect in treating a range of cancers.
https://www.pharmalive.com/wp-content/uploads/2021/03/Merck-KGaAs-ATR-Inhibitor-Shows-Promise-in-Both-Cancer-and-COVID-19-BioSpace-3-30-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-03-30 15:30:472021-03-31 11:45:38Merck KGaA’s ATR Inhibitor Shows Promise in Cancer and Covid-19